Psychosomatic Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karst, M.
Right arrow Articles by Passie, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karst, M.
Right arrow Articles by Passie, T.
Related Collections
Right arrow Musculoskeletal
Right arrow Pain
Right arrow Psychosis
Right arrow Somatoform
Psychosomatic Medicine 67:111-115 (2005)
© 2005 American Psychosomatic Society


ORIGINAL ARTICLES

Abnormality in the Self-monitoring Mechanism in Patients With Fibromyalgia and Somatoform Pain Disorder

Matthias Karst, MD, PhD, Niels Rahe-Meyer, MD, Ayhan Gueduek, MS, Ludwig Hoy, PhD, Mathias Borsutzky, MD and Torsten Passie, MD, MA

From the Department of Anesthesiology, Pain Clinic (M.K., N.R.-M., A.G.), the Department of Biometrics (L.H.), and the Department of Clinical Psychiatry and Psychotherapy (M.B., T.P.), Hannover Medical School, Hannover, Germany.

Address correspondence and reprint requests to Priv.-Doz. Dr. Matthias Karst, Hannover Medical School, Department of Anesthesiology, Pain Clinic, D-30625 Hannover, Germany. E-mail: karst.matthias{at}mh-hannover.de


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 NOTES
 REFERENCES
 
Background: Auditory hallucinations and passivity experiences are associated with an abnormality in the self-monitoring mechanism that normally allows us to distinguish self-produced from externally produced sensations. It is unclear if chronic central pain disorders such as fibromyalgia and somatoform pain disorders also involve a defect of the self-monitoring mechanism.

Methods: Responses to tactile stimulation were assessed in four groups of subjects (N = 40): patients with fibromyalgia, patients with somatoform pain disorder, patients with schizophrenia with auditory hallucinations and/or passivity experiences, and normal control subjects. The subjects were asked to rate the perception of a tactile sensation on their left and right hands. The tactile stimulation was either self-produced by movement of the subject's right or left hand or externally produced by the experimenter.

Results: Normal control subjects experienced self-produced stimuli as less intense than identical, externally produced tactile stimuli. In contrast, patients with fibromyalgia, patients with somatoform pain disorder, and patients with schizophrenia with auditory hallucinations and/or passivity experiences gave the same perceptual ratings for tactile stimuli produced by themselves as those produced by the experimenter (intergroup difference, p = .043; 95% confidence interval [CI], 0.16–0.68). Post hoc tests revealed that this significance was mainly caused by the fibromyalgia (p = .046; 95% CI, –1.66––0.13) and the somatoform pain disorder group (p = .033; 95% CI, –1.71––0.06).

Conclusions: We conclude that central pain disorders such as fibromyalgia and somatoform pain disorders interfere with the correct functioning of the self-monitoring mechanism that normally allows us to distinguish self-produced from externally produced tactile stimuli.

Key Words: fibromyalgia • somatoform pain disorder • schizophrenia • forward model • tickling

Abbreviations: FM = fibromyalgia; SPD = somatoform pain disorder; HP = hallucinations and/or passivity; NS = normal subjects; ACR = American College of Rheumatology; ICD = International Classification of Diseases; BPRS = Brief Psychiatric Rating Scale; SOMS = Screening for Somatoform Symptoms; DSM = Diagnostic and Statistical Manual of Mental Disorders; STAI = State-Trait-Anxiety Inventory; VAS = visual analog scale; SPS = self-produced tactile stimulus; EPS = externally produced tactile stimulus; ANOVA = one-way analysis of variance.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 NOTES
 REFERENCES
 
Fibromyalgia (FM) and somatoform pain disorders (SPD) are both chronic pain syndromes associated with low pain thresholds, consistent with the phenomenon of central sensitization (1–3). In patients with FM, a generalized increase in sensitivity was found that was unrelated to spontaneous pain (4). Patients with somatization proneness showed a significant increase in hypersensitivity to touch (5). Both observations are probably the result of central nervous system dysfunction, possibly involving central tactile processing.

Blakemore et al. (6,7) and Weiskrantz et al. (8) have previously shown that normal subjects perceived self-produced tactile stimuli as less intense, less sensitive, and less pleasant than externally produced tactile stimuli. These results were interpreted in terms of sensory predictions made by a forward model of the motor system (9). Impairment in this self-monitoring forward model as part of a self-monitoring mechanism was observed in subjects with auditory hallucinations and passivity phenomena (HP) associated with schizophrenia (10), but not in patients with schizophrenia who do not have HP. It has been suggested that these abnormal experiences arise through a lack of awareness of intended actions and predicted limb position (11).

Patients with chronic pain often report abnormal tactile sensitivity in the affected area, varying from hypoesthesia to allodynia (12). Earlier studies have indicated that alterations in afferent input lead to cortical reorganization of the sensory maps corresponding to the affected area (13). However, very little is known about the possible effects of chronic widespread pain on central tactile processing in general and on the self-monitoring mechanism in particular.

It was suggested that chronic widespread pain may not only affect tactile thresholds, but also the self-monitoring mechanism. It has been hypothesized that this effect is more pronounced in disturbances of central nervous origin. Therefore, we have assumed that there is a spectrum in the abnormality of the self-monitoring mechanism, ranging from patients with acute schizophrenia and patients with SPD to patients with FM and normal subjects (NS).

We examined this hypothesized association by comparing patients with FM and those with SPD with patients with acute schizophrenia (with HP) and NS, testing whether they could distinguish the sensory consequences of their own actions from externally produced tactile stimulation.


    METHOD
 TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 NOTES
 REFERENCES
 
Subjects
Responses to tactile stimulation were assessed in four groups of 10 subjects each: patients with FM (1 male/9 females, mean age 53.20 ± 7.81, 7 right-handed, 2 left-handed, 1 ambidextrous), patients with somatoform pain disorder (2 males/8 females, mean age 47.40 ± 9.48, 8 right-handed, 2 left-handed), patients with schizophrenia with auditory hallucinations and/or passivity experiences (4 males/6 females, mean age 39.10 ± 13.70, 9 right-handed, 1 left-handed), and normal control subjects (2 males/8 females, mean age 42.90 ± 14.53, all 10 right-handed). Patients were recruited from the pain clinic (patients with FM and those with SPD) and from the acute care unit of the Department of Clinical Psychiatry and Psychotherapy (patients with HP). They were told that the study was conducted to examine if perception may be altered under different conditions.

The patients with FM had a clinical presentation and examination consistent with the American College of Rheumatology (ACR) criteria, including the presence of chronic widespread pain in at least three body quadrants, as well as the axial skeleton and 11 to 18 fibromyalgia (FM) tender points, located at the occipital and lower cervical area, trapezius and supraspinatus muscle, second costosternal junction, both lateral epicondyles, gluteus muscle, greater trochanteric area, and the medial fat pads of the knees (14).

The patients with SPD had a clinical presentation and examination consistent with the International Classification of Diseases, 10th revision (ICD-10) criteria (15) for somatoform pain disorder (F.45.4), including chronic widespread pain associated with psychologic factors that could not be explained by any organic pathology or pathophysiological mechanism (3). Patients with a typical FM pattern and distribution of tender points were not considered as patients with SPD, even though psychologic factors were important features of their symptomatology.

The patients with the diagnosis of schizophrenia who had had auditory hallucinations and/or passivity experiences within the prior 6 weeks were diagnosed by clinical interview (by M.B.) using the ICD-10 criteria (15).

Age-matched healthy volunteers (NS) as controls were recruited by two of the authors (A.G., M.B.). Any specific diseases or disorders were excluded by a comprehensive clinical interview.

All patients and normal subjects were also assessed with the Brief Psychiatric Rating Scale (BPRS). We used a short form of the BPRS consisting of 18 symptom constructs (somatic concern, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement, disorientation), each to be rated by trained clinicians (M.B., M.K.) on a seven-point scale of severity ranging from "not present" to "extremely severe" (16). Additionally, all patients and normal subjects completed the Screening for Somatoform Symptoms (SOMS). The SOMS includes all somatic symptoms relevant for somatization disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), as well as according to ICD-10. The questionnaire consisted of 53 somatization symptoms, each to be rated on a four-point scale of severity ranging from "not present" to "extremely severe" (17,18). Furthermore, all patients and normal subjects completed the State-Trait-Anxiety Inventory (STAI X1 for the current state of the individual in terms of the level of transitory anxiety at the time the questionnaire was completed and STAI X2 to measure the general level of background anxiety with which an individual operates in normal life) (19), the visual analog scale for anxiety (VAS, range 0–10; 0 = no anxiety, 10 = strongest anxiety) (with VAS-anxiety: 1 = level of anxiety before the first 8 measurements and VAS-anxiety: 2 = level of anxiety before the second eight measurements), and, when appropriate, the VAS for pain (range 0–10; 0 = no pain, 10 = strongest pain), and a questionnaire about their medication.

The study protocol was approved by the Institutional Review Board, and written informed consent was obtained from all patients and volunteers.

Procedure
The tactile stimulus device consisted of a hand-fixing device in which a plastic pointer can be moved on the palm of the left or right hands. Thus, the hand was put on a hand layer and was fixed between a palmar and a padded dorsal wall. In the palmar wall, the pointer was projected through a U-shaped slot in which it could be moved. The pointer had a spherical tip of 1 mm in diameter and was counterweighted with a spring in a plastic rod to maintain a constant pressure of approximately 17 g on the palm (Figures 1 and 2). Subjects sat facing the table with their left arm perpendicular to the table and the left hand in the apparatus with the palm fixed tightly to the plastic pointer. The rod with the plastic pointer at its end could either be moved by the subjects using the right hand or by the experimenter. To examine the palm of the right hand, the whole apparatus was rotated 180°. The movement followed the U-shaped form of the slot on the palm and took place once per second for 4 seconds. Movements were synchronized with the beat of a metronome. Each subject was given eight trials in which the two conditions (self-administration of the tactile sensation or tactile sensation by the experimenter) were presented successively on the same palm for 4 seconds. To control for a possible sequence effect throughout the 16 trials, the sequence of the two conditions was balanced.



View larger version (79K):
[in this window]
[in a new window]
 
Figures 1 and 2. The tactile stimulus device consisted of a hand layer (6), a palmar wall (3) with a U-shaped slot (4) in which a plastic pointer (2) can be moved on the palm of the left or right hand and a dorsal wall (5). One hand was put on the hand layer (6) and fixed tightly with a screw fixation (1) between the palmar wall (3) and the padded dorsal wall (5). The other hand (for self-stimulation) or the experimenter (for external stimulation) could move a plastic rod with the pointer (2) at its end, following the U-shaped slot in the palmar wall (3). The pointer (2) had a spherical tip of 1-mm diameter and was counterweighted with a spring in the plastic rod to maintain a constant pressure of approximately 17 g on the palm during its movement. To obtain a maximum of convenience for the subjects during the procedure, the angle of the hand layer (6) was adjustable at its joint (7). The whole apparatus was movable but stable as a result of its firm basis (8).

 



View larger version (52K):
[in this window]
[in a new window]
 
Figures 1 and 2. The tactile stimulus device consisted of a hand layer (6), a palmar wall (3) with a U-shaped slot (4) in which a plastic pointer (2) can be moved on the palm of the left or right hand and a dorsal wall (5). One hand was put on the hand layer (6) and fixed tightly with a screw fixation (1) between the palmar wall (3) and the padded dorsal wall (5). The other hand (for self-stimulation) or the experimenter (for external stimulation) could move a plastic rod with the pointer (2) at its end, following the U-shaped slot in the palmar wall (3). The pointer (2) had a spherical tip of 1-mm diameter and was counterweighted with a spring in the plastic rod to maintain a constant pressure of approximately 17 g on the palm during its movement. To obtain a maximum of convenience for the subjects during the procedure, the angle of the hand layer (6) was adjustable at its joint (7). The whole apparatus was movable but stable as a result of its firm basis (8).

 
After each trial, subjects were instructed to rate the sensation on their palm on a scale from 0 (not at all) to 10 (extremely) "intense." Subjects were told that a rating of zero indicated a neutral perception for the scale. Subjects were also told that it was important to maintain the same scale throughout the experiment and that the emphasis was on the relative values of their judgments, not the absolute values.

Statistical Analysis
Based on the expected differences (mean perceptual rating difference between self-produced [SPS] and externally produced tactile stimulation [EPS] conditions for the four subject groups: HP, 0.1; SPD, 0.3; FM, 0.5; NS, 0.5) between mean values, the sample size required to achieve 90% power was calculated as 40 subjects for the whole group, assuming that the common standard deviation is 2.50. The differences were expected from the results of Blakemore et al. (7), who found a mean perceptual rating difference between self-produced and externally produced tactile stimulation conditions of approximately 0.5 for the normal control subjects and patients with schizophrenia without symptoms, in contrast to less than 0.1 in patients with schizophrenia with specific symptoms (HP).

We calculated the mean differences (EPS-SPS) between the perceptual ratings for SPS and EPS. Statistical analyses used one-way analysis of variance (one-way ANOVA). To compare each group against the normal subject group (NS), the two-sided post hoc Dunnett t test was used, with the NS group as control. To test for between-subject effects in regard to different medication, univariate analysis of variance with covariates was used. Differences were regarded as significant with p < .05. Results are reported as means ± standard deviations.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 NOTES
 REFERENCES
 
The groups did not differ significantly at baseline with respect to age, gender, STAIX1, STAIX2, VAS-anxiety 1, and VAS-pain. BPRS (p < .001 for all groups vs. NS), SOMS (p < .001 for FM vs. NS and p = .002 for SPD vs. NS), and the VAS-anxiety 2 (p = .006 for HP vs. NS) showed significant differences from the control group (Table 1). Taken together, the perceptual ratings were approximately 25% to 30% higher in the patient groups than in the NS group (Figure 3). With respect to the mean differences (EPS-SPS) between the perceptual ratings for SPS and EPS, the results showed significant intergroup differences (p = .043; 95% confidence interval [CI], 0.16–0.68). Post hoc tests revealed that this result was mainly produced by the difference FM versus NS (p = .046; 95% CI, –1.66––0.13) and SPD versus NS (p = .033; 95% CI, –1.71––0.06) and less by the difference HP versus NS (p = .108; 95% CI, –1.53–0.12) (Figure 3). Although the groups used different medication (consisting of antidepressants, anticonvulsants, opioids, and neuroleptics), there were no between-subject effects (p = .168 for antidepressants, p = .566 for opioids, p = .705 for anticonvulsants, and p = .333 for neuroleptics) (Table 1).


View this table:
[in this window]
[in a new window]
 
TABLE 1. Sample Characteristics (Baseline Values)

 


View larger version (27K):
[in this window]
[in a new window]
 
Figure 3. Perceptual ratings for self-produced tactile stimuli (SPS) and externally produced tactile stimuli (EPS) on the visual analog scale for sensation (VAS, 0 = not at all to 10 = extremely intense). A significant intergroup difference (p = .043, analysis of variance test) was found (p = .046 for FM vs. NS; p = .033 for SPD vs. NS, using two-sided post hoc Dunnett t test). No significant difference could be found for HP versus NS (p = .108, using two-sided post hoc Dunnett t test). FM = fibromyalgia; SPD = somatoform pain disorder; HP = hallucinations and passivity experiences; NS = normal subjects. In the figure, medians are represented by horizontal bars, interquartile ranges by boxes, ranges by error bars, and extreme values by circles. In the table, mean values and standard deviations (±) are indicated.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 NOTES
 REFERENCES
 
This is the first study of the self-monitoring mechanism in patients with chronic widespread pain. For this purpose, a mobile tactile stimulus device was constructed in which a plastic pointer can be moved on the palm with constant pressure. We demonstrate that patients with FM and those with SPD did not show a decrease in their perceptual ratings for tactile stimuli produced by themselves in comparison with those produced by the experimenter. This result indicates that 1) central pain disorders are associated with an abnormality in the self-monitoring mechanism that normally allows us to distinguish self-produced from externally produced sensations, and 2) that the underlying disturbances in the central tactile processing may not be limited to somatosensory processing regions in the central nervous system exclusively representing the painful area.

The baseline values of the clinically carefully characterized patient groups and the normal control subjects were well balanced with respect to age, gender, anxiety levels, and VAS-pain (FM and SPD group), giving a well-matched study population. Although there was a strong tendency to higher anxiety values in the HP group and the anxiety levels before the second eight measurements were significant higher (p = .006) than in the other groups, the differences in anxiety were not as marked as expected. This may be related to the trial setting, in which at least one of the investigators was almost always well known to the particular patient or volunteer.

The observed greater sensitivity in both the FM and the SPD groups than in the control group is concordant with the finding of hypersensitivity in such patient groups (4,5). Surprisingly, the pain disorder groups contributed more to the significantly reduced difference between the perceptual ratings for self-produced and externally produced stimuli than did the HP group, which argues against the spectrum theory mentioned in the "Introduction." Also surprisingly, there were essentially no differences in the results between the FM and SPD groups, which may be partly caused by the diagnostic overlap between the pain groups (see subsequently). The smaller difference in the perceptual rating differences in the HP group may be associated with a reduction in symptomatology by the treatment of current acute symptoms at the time of the investigation. This seems to correspond to the results of Blakemore et al. (10), who found that the presence of hallucinations and/or passivity experiences, and not the diagnosis "schizophrenia" itself, was associated with dysfunction of self-monitoring.

The limitations of the study are the small sample size in each group and the different distribution of medications across groups. However, if all medications or each medication had been included as additional covariates, no between-subject effects could have been calculated. Furthermore, antidepressants may reduce the perception of cutaneous stimulation (20). Although in our study a high proportion of patients in the pain groups took antidepressants, their ratings for cutaneous stimuli were 25% to 30% higher than the ratings of normal subjects. In addition, although each of the different compounds may impair the power of concentration, patients in the SPD and FM groups had been on stable doses for years, implying that acute cognitive impairment is unlikely. Another limitation of the study is the possibility of overlap between FM and SPD that could not have been totally ruled out by using the criteria mentioned here. Our patients with FM had an even higher score than the patients with SPD with respect to the SOMS scale, confirming that somatization is more common in patients with FM (21,22). An additional limitation may be seen in the lack of a control group with organically caused pain, in the traditional sense of the word, like cancer-related pain. However, although all patients with chronic pain specified their pain with the level of at least "modest to severe pain" (VAS 6–8), no one appeared to be obviously distressed during the tests. Therefore, we suggest that the observed effect is mainly caused by the central nervous dysfunction and not by spontaneous pain. This hypothesis is supported by functional imaging data, which indicated that a self-produced physical pain stimulus is modulated in a different way than a self-produced tactile stimulus (6,23).

We conclude that central pain disorders such as fibromyalgia and somatoform pain disorders interfere with the correct functioning of the self-monitoring mechanism, as defined by the work of Frith et al. (11). Results of the present study suggest that the amount of sensory attenuation after self-produced sensory stimuli decreases in patients who are chronically exposed to endogenous pain signals. It may be hypothesized that the attenuation of the ability to distinguish between internal and external stimuli may be caused by dedifferentiation of the highly complex psychophysiological feedback systems, equivalent to an earlier phylogenetic pattern of functioning. The neurophysiological background for this may be different activities of modulating cerebellar structures (6) that are probably more involved in acute (23–25) and chronic pain conditions than is usually recognized.

Future studies could combine the presented results with functional magnetic resonance imaging.

The authors thank Gabriele Huwald, RN (Pain Clinic, Hannover Medical School) for her skillful technical assistance and all patients and volunteers for their patient participation in this study.


    NOTES
 TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 NOTES
 REFERENCES
 
Received for publication February 17, 2004; revision received August 10, 2004.

DOI:10.1097/01.psy.0000146327.73705.9c


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 NOTES
 REFERENCES
 

  1. Weigent DA, Bradley LA, Blalock JE, Alarcon GS. Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 1998;315:405–12.[CrossRef][Medline]
  2. Staud R, Domingo MA. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med 2001;2:208–15.[Medline]
  3. Kellner R. Psychosomatic syndromes, somatization and somatoform disorders. Psychother Psychosom 1994;61:4–24.[CrossRef][Medline]
  4. Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996;68:375–83.[CrossRef][Medline]
  5. Sivik T. Alexithymia and hypersensitivity to touch and palpation. Integr Physiol Behav Sci 1993;28:130–6.[Medline]
  6. Blakemore S-J, Wolpert DM, Frith CD. Central cancellation of self-produced tickle sensation. Nat Neurosci 1998;1:635–40.[CrossRef][Medline]
  7. Blakemore S-J, Wolpert DM, Frith CD. Why can't you tickle yourself? Neuroreport 2000;11:11–6.
  8. Weiskrantz L, Elliott J, Darlington C. Preliminary observations on tickling oneself. Nature 1971;230:598–9.[CrossRef][Medline]
  9. Frith CD. The Cognitive Neuropsychology of Schizophrenia. London: LEA; 1992.
  10. Blakemore S-J, Smith J, Steel R, Johnstone EG, Frith CD. The perception of self-produced sensory stimuli in patients with auditory hallucinations and passivity experiences: evidence for a breakdown in self-monitoring. Psychol Med 2000;30:1131–9.[CrossRef][Medline]
  11. Frith CD, Blakemore S-J, Wolpert DM. Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. Brain Res Rev 2000;31:357–63.[CrossRef][Medline]
  12. Moriwaki K, Yuge O. Topographical features of cutaneous tactile hypoesthetic and hyperesthetic abnormalities in chronic pain. Pain 1999;81:1–6.[Medline]
  13. Juottonen K, Gockel M, Silén T, Hurri H, Hari R, Forss N. Altered central sensorimotor processing in patients with complex regional pain syndrome. Pain 2002;98:315–23.[CrossRef][Medline]
  14. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72.[Medline]
  15. International Classification of Diseases-10 (ICD-10): Classification of Mental and Behavioural Disorders. Geneva: World Health Organization; 1992.
  16. Lukoff D, Liberman R, Nuechterlein K. Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophr Bull 1986;12:578–602.
  17. Rief W, Hiller W, Heuser J. SOMS-Das Screening für Somatoforme Störungen. Manual zum Fragebogen. [SOMS-the screening for somatoform symptoms. Manual for the self-rating scale.] Bern: Huber-Verlag; 1997.
  18. Rief W, Hiller W. Toward empirically based criteria for the classification of somatoform disorders. J Psychosom Res 1999;46:507–18.[CrossRef][Medline]
  19. Spielberger CD, Gorsuch RL, Lushene RE. State-Trait-Anxiety-Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
  20. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998;275:G460–6.
  21. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003;65:528–33.[Abstract/Free Full Text]
  22. Kirmayer LJ, Robbins JM, Kapusta MA. Somatization and depression in fibromyalgia syndrome. Am J Psychiatry 1988;145:950–4.[Abstract/Free Full Text]
  23. Mohr C, Erdmann C, Binkofski F, Helmchen C. Unterschiede in der zentralen Schmerzrepräsentation bei selbst- vs. fremd-zugeführten thermischen Schmerzreizen: eine fMRT-Studie. [Differences of the central pain representation with self and externally applicated noxious thermal stimuli: a fMRT study.] Schmerz 2003;17:S71.
  24. Saab CY, Willis WD. Nociceptive visceral stimulation modulates the activity of cerebellar Purkinje cells. Exp Brain Res 2001;140:122–6.[CrossRef][Medline]
  25. Helmchen C, Mohr C, Erdmann C, Petersen D, Nitschke MF. Differential cerebellar activation related to perceived pain intensity during noxious thermal stimulation in humans: a functional magnetic imaging study. Neurosci Lett 2003;335:202–6.[Medline]




This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karst, M.
Right arrow Articles by Passie, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karst, M.
Right arrow Articles by Passie, T.
Related Collections
Right arrow Musculoskeletal
Right arrow Pain
Right arrow Psychosis
Right arrow Somatoform


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS